Which patients with prostate cancer are actually candidates for hormone therapy?
AUTOR(ES)
Sciarra, Alessandro, Cardi, Antonio, Salvatori, Gianfilippo, D'Eramo, Giuseppe, Mariotti, Gianna, Di Silverio, Franco
FONTE
International braz j urol
DATA DE PUBLICAÇÃO
2004-12
RESUMO
In this article, we will try to address the following aspects: which factors are responsible of the introduction of new candidates for hormone therapy in prostate cancer, who are actually candidates for hormone therapy, classifying them on the basis of the stage of the disease, and which treatment modalities can be proposed for each candidate. Since the introduction of hormone therapy for the treatment of prostate cancer, there has been a debate about the optimal timing of hormone therapy. A modification in the timing of hormone therapy produced new candidates for hormone manipulation. In particular, the use of hormone treatment for younger patients, longer periods and early prostate cancer, absolutely requires a whole re-evaluation of which therapy is indicated and it may produce new problems such as higher risk of over-treatment, need of a better evaluation of quality of life in younger patients and the research for better tolerated therapies. Therapies that resist for longer periods without the production of a hormone-refractory disease are also required.
Documentos Relacionados
- Transperineal versus transrectal prostate biopsy for predicting the final laterality of prostate cancer: are they reliable enough to select patients for focal therapy? Results from a multicenter international study
- Obesity and poor breast cancer prognosis: an illusion because of hormone replacement therapy?
- Autophagy and intermittent fasting: the connection for cancer therapy?
- Analysis of monotherapy prostate brachytherapy in patients with prostate cancer. Initial PSA and Gleason are important for recurrence?
- Significance of prostate adenocarcinoma perineural invasion on biopsy in patients who are otherwise candidates for active surveillance